Literature DB >> 35105962

Mechanisms of immune activation and regulation: lessons from melanoma.

Shelly Kalaora1, Adi Nagler1, Jennifer A Wargo2,3, Yardena Samuels4.   

Abstract

Melanoma, a skin cancer that develops from pigment cells, has been studied intensively, particularly in terms of the immune response to tumours, and has been used as a model for the development of immunotherapy. This is due, in part, to the high mutational burden observed in melanomas, which increases both their immunogenicity and the infiltration of immune cells into the tumours, compared with other types of cancers. The immune response to melanomas involves a complex set of components and interactions. As the tumour evolves, it accumulates an increasing number of genetic and epigenetic alterations, some of which contribute to the immunogenicity of the tumour cells and the infiltration of immune cells. However, tumour evolution also enables the development of resistance mechanisms, which, in turn, lead to tumour immune escape. Understanding the interactions between melanoma tumour cells and the immune system, and the evolving changes within the melanoma tumour cells, the immune system and the microenvironment, is essential for the development of new cancer therapies. However, current research suggests that other extrinsic factors, such as the microbiome, may play a role in the immune response to melanomas. Here, we review the mechanisms underlying the immune response in the tumour and discuss recent advances as well as strategies for treatment development.
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35105962     DOI: 10.1038/s41568-022-00442-9

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   69.800


  174 in total

1.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

Authors:  Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean-Jacques Grob; Vanna Chiarion-Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Suzanne Swann; Jeffrey J Legos; Fan Jin; Bijoyesh Mookerjee; Keith Flaherty
Journal:  Lancet       Date:  2015-05-31       Impact factor: 79.321

2.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

3.  Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

Authors:  Margaret K Callahan; Harriet Kluger; Michael A Postow; Neil H Segal; Alexander Lesokhin; Michael B Atkins; John M Kirkwood; Suba Krishnan; Rafia Bhore; Christine Horak; Jedd D Wolchok; Mario Sznol
Journal:  J Clin Oncol       Date:  2017-10-17       Impact factor: 44.544

4.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

Review 5.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

Review 6.  Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.

Authors:  Thomas F Gajewski
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 7.  The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.

Authors:  Andrea Anichini; Claudia Vegetti; Roberta Mortarini
Journal:  Cancer Immunol Immunother       Date:  2004-06-03       Impact factor: 6.968

8.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

9.  Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.

Authors:  M L Salgaller; J S Weber; S Koenig; J R Yannelli; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

Review 10.  Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.

Authors:  Eryn Blass; Patrick A Ott
Journal:  Nat Rev Clin Oncol       Date:  2021-01-20       Impact factor: 65.011

View more
  8 in total

1.  AURKA is a prognostic potential therapeutic target in skin cutaneous melanoma modulating the tumor microenvironment, apoptosis, and hypoxia.

Authors:  ShengYong Long; Xuan Fen Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-23       Impact factor: 4.322

2.  Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management.

Authors:  Zaoqu Liu; Hui Xu; Siyuan Weng; Chunguang Guo; Qin Dang; Yuyuan Zhang; Yuqing Ren; Long Liu; Libo Wang; Xiaoyong Ge; Zhe Xing; Jian Zhang; Peng Luo; Xinwei Han
Journal:  Cancer Immunol Immunother       Date:  2022-08-23       Impact factor: 6.630

3.  An Immune-Related Long Noncoding RNA Pair as a New Biomarker to Predict the Prognosis of Patients in Breast Cancer.

Authors:  Hanwen Jiang; Jingxian Sun; Fucong Liu; Xincai Wu; Zhaohui Wen
Journal:  Front Genet       Date:  2022-06-22       Impact factor: 4.772

4.  Promising prognostic value of Transglutaminase type 2 and its correlation with tumor-infiltrating immune cells in skin cutaneous melanoma.

Authors:  Silvia Muccioli; Roberto Ciaccio; Valentina Brillo; Luigi Leanza
Journal:  Cell Death Discov       Date:  2022-06-20

5.  Sample-Specific Perturbation of Gene Interactions Identifies Pancreatic Cancer Subtypes.

Authors:  Ran Wei; Huihui Zhang; Jianzhong Cao; Dailei Qin; Shengping Li; Wuguo Deng
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

6.  T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy.

Authors:  Soizic Garaud; Marie-Caroline Dieu-Nosjean; Karen Willard-Gallo
Journal:  Nat Commun       Date:  2022-04-26       Impact factor: 17.694

Review 7.  RNA modifications: importance in immune cell biology and related diseases.

Authors:  Lian Cui; Rui Ma; Jiangluyi Cai; Chunyuan Guo; Zeyu Chen; Lingling Yao; Yuanyuan Wang; Rui Fan; Xin Wang; Yuling Shi
Journal:  Signal Transduct Target Ther       Date:  2022-09-22

8.  Photothermal Nano-Vaccine Promoting Antigen Presentation and Dendritic Cells Infiltration for Enhanced Immunotherapy of Melanoma via Transdermal Microneedles Delivery.

Authors:  Jiaojiao Zhu; Ruimin Chang; Benliang Wei; Yao Fu; Xiang Chen; Hong Liu; Wenhu Zhou
Journal:  Research (Wash D C)       Date:  2022-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.